Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

220 views

Published on

Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017SummaryGlobalData, the industry analysis specialist, has released its new report, 'Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017'. The report is an essential source of information and analysis on the global uveitis market. The report identifies the key trends shaping and driving the global uveitis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global uveitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.GlobalData expects the global uveitis therapeutics market to grow at 26.4% annually for the next seven years, from $317m in 2010 to reach $1.6 billion by 2017. This significant growth is primarily attributed to increasing therapeutic options for the treatment of uveitis. In addition, the successful launch of some targeted therapies such as Luveniq (voclosporin), AIN457 and the approval of Humira may significantly stimulate market growth in the near future. However, the complex etiology of the condition will continue to be a barrier for market growthScopeThe report provides information on the key drivers and challenges of the uveitis market. Its scope includes - - Annualized global uveitis market revenues data from 2005 to 2010, forecast for seven years to 2017.- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as calcineurin inhibitor, interleukin inhibitor, tnf-' inhibitor, pkc inhibitor, mtor inhibitor, plasminogen activator, immune regulation and so on.- Analysis of the current and future competition in the global uveitis market. Key market players covered are Lux Biosciences, Novartis, and Abbott Laboratories.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the uveitis market.- Analysis of key recent licensing and partnership agreements in uveitis marketReasons to buyThe report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global uveitis market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global uveitis market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.- What's the next big thing in the global uveitis market landscape' ' Identify, understand and capitalize.

  • Be the first to comment

  • Be the first to like this

Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to2017Published on April 2011 Report SummaryUveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017SummaryGlobalData, the industry analysis specialist, has released its new report, Uveitis Therapeutics - Pipeline Assessment and MarketForecasts to 2017. The report is an essential source of information and analysis on the global uveitis market. The report identifies thekey trends shaping and driving the global uveitis market. The report also provides insights on the prevalent competitive landscape andthe emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the reportprovides valuable insights on the pipeline products within the global uveitis sector. This report is built using data and informationsourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.GlobalData expects the global uveitis therapeutics market to grow at 26.4% annually for the next seven years, from $317m in 2010 toreach $1.6 billion by 2017. This significant growth is primarily attributed to increasing therapeutic options for the treatment of uveitis.In addition, the successful launch of some targeted therapies such as Luveniq (voclosporin), AIN457 and the approval of Humira maysignificantly stimulate market growth in the near future. However, the complex etiology of the condition will continue to be a barrier formarket growthScopeThe report provides information on the key drivers and challenges of the uveitis market. Its scope includes -- Annualized global uveitis market revenues data from 2005 to 2010, forecast for seven years to 2017.- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends.Pipeline candidates fall under major therapeutic classes such as calcineurin inhibitor, interleukin inhibitor, tnf- inhibitor, pkc inhibitor,mtor inhibitor, plasminogen activator, immune regulation and so on.- Analysis of the current and future competition in the global uveitis market. Key market players covered are Lux Biosciences,Novartis, and Abbott Laboratories.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide aqualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for theuveitis market.- Analysis of key recent licensing and partnership agreements in uveitis marketReasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and byidentifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global uveitis market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely toUveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 1/8
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!impact the global uveitis market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance ofvarious competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitiveadvantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunitiesfor consolidations, investments and strategic partnerships.- Whats the next big thing in the global uveitis market landscape Identify, understand and capitalize. Table of Content1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 52 Uveitis Therapeutics: Introduction 62.1 Overview 62.2 Etiology and Pathophysiology 72.3 Epidemiology 82.4 Symptoms 82.5 Diagnosis 82.5.1 Visual Acuity and External Examination: 82.5.2 Slit-lamp Examination: 82.5.3 Tonometry 82.5.4 Supplemental Examination: 92.6 Treatment and Management Pattern 92.7 GlobalData Pipeline Report Guidance 103 Uveitis Therapeutics: Market Characterization 113.1 Overview 113.2 Uveitis Therapeutics Market Size 113.3 Uveitis Therapeutics Market Size (2005-2010) Global 113.4 Uveitis Therapeutics Market Forecast (2010-2017) Global 123.5 Uveitis Therapeutics Market Size (2005-2010) US 133.6 Uveitis Therapeutics Market Forecast (2010-2017) US 143.7 Uveitis Therapeutics Market Size (2005-2010) France 153.8 Uveitis Therapeutics Market Forecast (2010-2017) France 163.9 Uveitis Therapeutics Market Size (2005-2010) Germany 173.10 Uveitis Therapeutics Market Forecast (2010-2017) Germany 183.11 Uveitis Therapeutics Market Size (2005-2010) Italy 193.12 Uveitis Therapeutics Market Forecast (2010-2017) Italy 203.13 Uveitis Therapeutics Market Size (2005-2010) Spain 213.14 Uveitis Therapeutics Market Forecast (2010-2017) Spain 223.15 Uveitis Therapeutics Market Size (2005-2010) UK 233.16 Uveitis Therapeutics Market Forecast (2010-2017) UK 243.17 Uveitis Therapeutics Market Size (2005-2010) Japan 253.18 Uveitis Therapeutics Market Forecast (2010-2017) Japan 26Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 2/8
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!3.19 Drivers and Barriers 273.19.1 Drivers for the Uveitis Therapeutics Market 273.19.2 Barriers for the Uveitis Therapeutics Market 273.20 Opportunity and Unmet needs 283.21 Key Takeaway 294 Uveitis Therapeutics Market Competitive Assessment 304.1 Overview 304.2 Strategic Competitor Assessment 304.3 Product Profile for the Major Marketed Products in Uveitis Therapeutics Market 314.3.1 Overview 314.3.2 Corticosteroids 314.3.3 Immunosuppressants 314.4 Key Takeaway 315 Uveitis Therapeutics: Pipeline Assessment 325.1 Overview 325.2 Strategic Pipeline Assessment 325.3 Pipeline by Phases of Development 325.3.1 Uveitis Therapeutics Regulatory Filed Products 325.3.2 Uveitis Therapeutics-Phase III Pipeline 335.3.3 Uveitis Therapeutics-Phase II Pipeline 335.3.4 Uveitis Therapeutics-Phase I Pipeline 335.3.5 Uveitis Therapeutics-Pre-Clinical Pipeline 335.4 Uveitis Therapeutics MarketPipeline by Mechanism of Action. 345.5 Technology Trends Analytic Framework 355.6 Promising Drugs Under Clinical Development 365.7 Profile for Promising Drugs 375.7.1 Luveniq 375.7.2 AIN457 (secukinumab) 385.7.3 Humira 385.8 Key Takeaway 396 Uveitis Therapeutics:Clinical Trials Mapping 406.1 Clinical Trials by Region/Country (US, EU5 and Japan) 406.2 Clinical Trials by Phase 416.3 Clinical Trials by Trial Status 426.4 Prominent Sponsors 436.5 Top Ten Companies Participating in Therapeutics Clinical Trials 447 Uveitis Therapeutics:Strategic Assessment 457.1 Key Events Impacting the Future Market 457.2 Future Market Competition Scenario 458 Uveitis:Future Players 478.1 Introduction 478.2 Company Profiles 478.2.1 Lux Biosciences 478.2.2 Novartis 488.2.3 Abbott Laboratories 518.2.4 Allergan 538.3 Other Companies in Uveitis Therapeutics Market 569 Uveitis Therapeutics: Liscensing and Partnership Deals 57Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 3/8
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!10 Appendix 5810.1 Market Definitions 5810.2 Abbreviations 5810.3 Methodology 5810.3.1 Coverage 5910.3.2 Secondary Research 5910.3.3 Forecasting 5910.3.4 Primary Research 6110.3.5 Expert Panel Validation 6210.4 Contact Us 6210.5 Disclaimer 6210.6 Bibliography 621.1 List of TablesTable 1: Uveitis- Anatomical Classification 6Table 2: Uveitis- Classification Based On Severity 6Table 3: Uveitis Therapeutics Market, Global, Revenue ($m), 2005-2010 11Table 4: Uveitis Therapeutics Market, Global, Forecast ($m), 2010-2017 12Table 5: Uveitis Therapeutics Market, US, Revenue ($m), 2005-2010 13Table 6: Uveitis Therapeutics Market, US, Forecast ($m), 2010-2017 14Table 7: Uveitis Therapeutics Market, France, Revenue ($m), 2005-2010 15Table 8: Uveitis Therapeutics Market, France, Forecast ($m), 2010-2017 16Table 9: Uveitis Therapeutics Market, Germany, Revenue ($m), 2005-2010 17Table 10: Uveitis Therapeutics Market, Germany, Forecast ($m), 2010-2017 18Table 11: Uveitis Therapeutics Market, Italy, Revenue ($m), 2005-2010 19Table 12: Uveitis Therapeutics Market, Italy, Forecast ($m), 2010-2017 20Table 13: Uveitis Therapeutics Market, Spain, Revenue ($m), 2005-2010 21Table 14: Uveitis Therapeutics Market, Spain, Forecast ($m), 2010-2017 22Table 15: Uveitis Therapeutics Market, UK, Revenue ($m), 2005-2010 23Table 16: Uveitis Therapeutics Market, UK, Forecast ($m), 2010-2017 24Table 17: Uveitis Therapeutics Market, Japan, Revenue ($m), 2005-2010 25Table 18: Uveitis Therapeutics Market, Japan, Forecast ($m), 2010-2017 26Table 19: Uveitis Therapeutics Regulatory Filed Products, 2011 32Table 20: Uveitis Therapeutics Phase III Pipeline, 2011 33Table 21: Uveitis Therapeutics Phase II Pipeline, 2011 33Table 22: Uveitis Therapeutics Phase I Pipeline, 2011 33Table 23: Uveitis Therapeutics Pre-Clinical Pipeline, 2011 33Table 24: Uveitis Therapeutics Most Promising Drugs Under Clinical Development, 2011 36Table 25: Uveitis Therapeutics Clinical Trials by Region, 2011 40Table 26: Uveitis Therapeutics Clinical Trials by Phase of Development, 2011 41Table 27: Uveitis Therapeutics Clinical Trials by Trial Status, 2011 42Table 28: Uveitis Therapeutics Clinical Trials by Prominent Sponsors, 2011 44Table 29: Uveitis Therapeutics Clinical Trials by Top Companies, 2011 44Table 30: Lux Biosciences Ophthalmology Pipeline Products, 2010 48Table 31: Lux Biosciences Ophthalmology Pipeline Products, 2010 48Table 32: Novartis Ophthalmology Pipeline Products, 2010 49Table 33: Novartis Ophthalmology Pipeline Products, 2010 49Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 4/8
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Table 34: Novartis-Deals, 2009-2011 50Table 35: Abbott Ophthalmology Pipeline Products, 2010 52Table 36: Abbott Laboratories- Deals, 2009-2011 52Table 37: Allergan-Ophthalmology Pipeline Products, 2010 55Table 38: Allergan-Deals, 2010-2011 55Table 39: Uveitis Therapeutics Market Future Players 56Table 40: Uveitis Therapeutics, Global, Deals, 2009-2011 571.2 List of FiguresFigure 1: Etiology of Uveitis 7Figure 2: Uveitis - Treatment and Management Pattern 9Figure 3: Uveitis Therapeutics Market, Global, Revenue ($m), 2005-2010 11Figure 4: Uveitis Therapeutics Market, Global, Forecast ($m), 2010-2017 12Figure 5: Uveitis Therapeutics Market, US, Revenue ($m), 2005-2010 13Figure 6: Uveitis Therapeutics Market, US, Forecast ($m), 2010-2017 14Figure 7: Uveitis Therapeutics Market, France, Revenue ($m), 2005-2010 15Figure 8: Uveitis Therapeutics Market, France, Forecast ($m), 2010-2017 16Figure 9: Uveitis Therapeutics Market, Germany, Revenue ($m), 2005-2010 17Figure 10: Uveitis Therapeutics Market, Germany, Forecast ($m), 2010-2017 18Figure 11: Uveitis Therapeutics Market, Italy, Revenue ($m), 2005-2010 19Figure 12: Uveitis Therapeutics Market, Italy, Forecast ($m), 2010-2017 20Figure 13: Uveitis Therapeutics Market, Spain, Revenue ($m), 2005-2010 21Figure 14: Uveitis Therapeutics Market, Spain, Forecast ($m), 2010-2017 22Figure 15: Uveitis Therapeutics Market, UK, Revenue ($m), 2005-2010 23Figure 16: Uveitis Therapeutics Market, UK, Forecast ($m), 2010-2017 24Figure 17: Uveitis Therapeutics Market, Japan, Revenue ($m), 2005-2010 25Figure 18: Uveitis Therapeutics Market, Japan, Forecast ($m), 2010-2017 26Figure 19: Opportunity and Unmet Need in the Uveitis Therapeutics Market 28Figure 20: Uveitis Therapeutics Strategic Competitor Assessment, 2010 30Figure 21: Uveitis Therapeutics Pipeline by Phase of Development, 2011 32Figure 22: Uveitis Therapeutics Pipeline by Mechanism of Action, 2011 34Figure 23: Uveitis Therapeutics Technology Trends Analytic Framework, 2011 35Figure 24: Uveitis Therapeutics Technology Trends Analytic Framework Description, 2011 36Figure 25: Luveniq-Clinical Trial Details 37Figure 26: Humira-Clinical Trial Details 38Figure 27: Uveitis Therapeutics Clinical Trials by Region, 2011 40Figure 28: Uveitis Therapeutics Clinical Trials by Phase of Development, 2011 41Figure 29: Uveitis Therapeutics Clinical Trials by Trial Status, 2011 42Figure 30: Uveitis Therapeutics Clinical Trials by Overall Sponsors, 2011 43Figure 31: Uveitis Therapeutics Clinical Trials by Prominent Sponsors, 2011 43Figure 32: Uveitis Therapeutics Market, Global, Clinical Trials by Top Companies, 2010 44Figure 33: Uveitis Therapeutics Market, Drivers and Restraints 2010 45Figure 34: Implications for Future Market Competition in the Uveitis Therapeutics Market, 2010 46Figure 35: Uveitis Therapeutics Market Pipeline by Company, 2010 47Figure 36: GlobalData Market Forecasting Model 61Companies MentionedUveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 5/8
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Lux BiosciencesNovartisAbbott LaboratoriesAllerganUveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 6/8
  7. 7. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 000.00 Quantity: _____ Site License--USD 4 000.00 Quantity: _____ Corporate License--USD 6 000.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 7/8
  8. 8. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 8/8

×